Showing 10 posts of 10 posts found.


FDA approve valsartan generic after shortages of supply

March 13, 2019
Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan

The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …


MHRA issues recall of irbesartan blood pressure meds over carcinogen contamination concerns

January 4, 2019
Manufacturing and Production, Medical Communications MHRA, irbesartan, pharma, sartan, valsartan

Following a number of recalls issued in the US and Europe in the latter half of 2018 for the blood …


FDA expands list of valsartan recalls

August 9, 2018
Medical Communications China, FDA, US, heart medication, recall, valsartan

The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled. …


EMA issues global recall of heart drugs over cancer risk contamination

July 10, 2018
Manufacturing and Production EMA, Europe, heart disease, pharma, valsartan

Several drugs designed for the treatment of high blood pressure and heart conditions have been recalled across Europe over fears …


FDA approves Allergan hypertension fixed-dose combo, Byvalson

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan

Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …

Novartis image

Novartis sales below forecast in ‘transformative’ year

January 28, 2015
Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan

Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …

Novartis heart drug sees stellar results

September 1, 2014
Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan

Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …

novartis image

Novartis faces data fraud charges in Japan

July 3, 2014
Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan

Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …

Diovan image

Ranbaxy’s Diovan copycat approved in US

June 27, 2014
Manufacturing and Production, Sales and Marketing Diovan, FDA, Novartis, Ranbaxy, blood pressure, sun pharmaceuticals, valsartan

Ranbaxy has won approval for its copycat form of Novartis’ blockbuster blood pressure drug Diovan, as the Swiss firm finally …

Latest content